Clinical Trial Update: An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Open-label dose-escalation trial of INCB054329 in patients with advanced solid tumors and hematologic malignancies has terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumors

Drugs mentioned

• INCB054329

Snippet

Sponsor: Incyte Corporation | Conditions: Solid Tumors and Hematologic Malignancy | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-06-14